Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Chronic Dermatologic Care: Baldo Scassellati Sforzolini from Galderma in Conversation with PharmaShots
Chronic Dermatologic Care: Baldo Scassellati Sforzolini from Galderma in Conversation with PharmaShots
Shots: Recently, the groundbreaking results from Galderma’s Phase III OLYMPIA 1 trial were published in JAMA Dermatology. The study evaluated nemolizumab in patients with moderate-to-severe active prurigo nodularis The trial met all primary and secondary endpoints, with results aligning with those from the OLYMPIA 2 trial, reinforcing nemolizumab’s potential in achieving sustained improvements in the…
May 26, 2025
Infusing Automation: Suresh Kannan from Model N in an Illuminating Discussion with PharmaShots
Infusing Automation: Suresh Kannan from Model N in an Illuminating Discussion with PharmaShots
Shots: Identifying discrepancies remains a key challenge for manufacturers in mitigating revenue leakage and ensuring alignment with payer plans Suresh Kannan, Model N’s Chief Product Officer, offers insights into the newly launched GenAI and enhanced data solutions aimed at optimizing revenue and ensuring compliance He also outlines a strategic approach to formulary identification and emphasizes…
May 21, 2025
Advancing Lupus Research: Devon Kelly from Lupus Nexus in a Stimulating Conversation with PharmaShots
Advancing Lupus Research: Devon Kelly from Lupus Nexus in a Stimulating Conversation with PharmaShots
Shots: Research into Lupus has yielded groundbreaking results in pharmacokinetics and pharmacodynamics, yet experts still don't understand its cause Lupus Research Alliance (LRA) recently launched a platform called Data Repository, Exchange, and Analytics (DREAM) for data sharing and partnerships for research in lupus Devon Kelly, Director of Lupus Nexus at the Lupus Research Alliance, sheds…
May 19, 2025
Takeda at AASLD 2024: Chinwe Ukomadu in a Riveting Dialogue Exchange with PharmaShots
Takeda at AASLD 2024: Chinwe Ukomadu in a Riveting Dialogue Exchange with PharmaShots
Shots:  AATD-associated liver disease is a progressive genetic disorder with no approved therapy, and liver transplantation remains the only option for patients with end-stage disease. Fazirsiran is an investigational RNAi therapy designed to treat AATD-associated liver disease by lowering the production of Z-AAT. PharmaShots welcomes Dr. Chinwe Ukomadu, Head of the Gastrointestinal and Inflammation Therapeutic…
May 5, 2025
Viewpoints_Jesse Mendelsohn
Predicting 2025 Trends: Jesse Mendelsohn from Model N in an Illuminating Discussion with PharmaShots
Shots: Several undulating factors coalesce to inadvertently shape the biopharma industry Prominent challenges include mounting pressure on Pharmacy Benefit Managers from independent pharmacies and drug manufacturers, a growing shortage of GLP-1 drugs, and the addition of 15 more drugs to the Inflation Reduction Act’s price negotiation list. Jesse Mendelsohn, SVP at Model N, emphasizes the…
April 28, 2025
Viewpoints_Vijay Nadipelli
Evaluating SDoH in SLE: Vijay Nadipelli from GSK in a Riveting Conversation with PharmaShots
Shots: SDoH screening can help identify patient needs, support faster clinical decisions, and improve patient-centric care A first-of-its-kind lupus study surveyed 69 patients across two institutions to assess the feasibility of routine SDoH screening in lupus clinics and identify related barriers and enablers at the physician, care team, and patient levels Vijay Nadipelli, Senior Director…
April 21, 2025
Viewpoints_Anton Yarovoy
Driving Precision Medicine Education: A Star Wars-Themed Talk on a Needed Approach
Shots:   Precision Medicine is a rapidly evolving field offering targeted treatments for optimal patient care   Education around testing is a critical need as many barriers exist that create practice gaps to patient identification  Testing State Awareness (TSA) is a critical component that needs to complement Brand and Disease State Awareness campaigns   Anton Yarovoy, Group Product…
April 18, 2025
Viewpoints_Kate Flathers
Streamlining Pharmaceutical Claims: Kate Flathers from Kalderos in a Stimulating Conversation with PharmaShots
Shots:  Streamlining claims transactions remains a major challenge for pharmaceutical manufacturers. The financial leakage owing to non-compliant and duplicate claims costs manufacturers a fortune  Using Kalderos' Truzo platform, manufacturers can pay covered entities directly while maintaining transparency and compliance Kate Flathers, Chief Product Officer at Kalderos, addresses the need for a compliant model for claims…
April 17, 2025
Viewpoints_Raphaël Ortiz
Enhancing Diagnostic Capabilities in Prostate Cancer: Raphaël Ortiz from Telix Pharmaceuticals in a Riveting Conversation with PharmaShots
Shots: Telix Pharmaceuticals’ Illuccix is approved in the UK for detecting and localizing prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, using PET imaging. Amidst a shortage of PET imaging agents in the UK and mainland Europe, Telix Pharmaceuticals has secured a significant advantage through an exclusive distribution partnership with Xiel Limited Raphaël…
April 7, 2025
Viewpoints_Roger Levy
Evaluating SDoH in Lupus Nephritis: Roger Levy from GSK in a Stimulating Conversation with PharmaShots
Shots: GSK presented data at the American College of Rheumatology from a multi-center cohort study highlighting the achievement of complete renal response in patients with active lupus nephritis The study evaluated the attainment of modified complete renal response (mCRR) in patients with systemic lupus erythematosus (SLE) and active lupus nephritis (LN), comparing characteristics between mCRR…
April 2, 2025
Load more